Fibromyalgia Treatment Market Size

  • Report ID: 4467
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Fibromyalgia Treatment Market Size

Fibromyalgia Treatment Market size was over USD 226.91 million in 2024 and is anticipated to exceed USD 710.71 million by the end of 2037, witnessing over 9.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of fibromyalgia treatment is evaluated at USD 243.61 million. The growth of the market is primarily ascribed to the worldwide escalating load of chronic pain. Fibromyalgia, according to researchers, increases painful sensations by altering how the brain and spinal cord receive painful and non-painful impulses. As per the World Health Organization (WHO), nearly 1.71 billion people around the world have been suffering from musculoskeletal disorders.

Fibromyalgia, commonly known as fibromyalgia syndrome, is a severe neurologic condition that results in immense pain throughout the body. This condition affects people physically, intellectually, and socially and causes exhaustion, musculoskeletal pain, and localized discomfort. Furthermore, there are only a few drugs, such as milnacipran, and pregabalin which are prescribed for fibromyalgia treatment. Globally rising occurrence of musculoskeletal disorder is leading to increased chances of fibromyalgia. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 10 million people in the United States.


Fibromyalgia Treatment Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4467
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of fibromyalgia treatment is evaluated at USD 243.61 million.

The fibromyalgia treatment market size was over USD 226.91 million in 2024 and is anticipated to exceed USD 710.71 million by the end of 2037, witnessing over 9.1% CAGR during the forecast period i.e., between 2025-2037. Worldwide growing incidences of road accidents, surge in post-traumatic stress disorder (PTSD), and worldwide boost in geriatric population will drive the market growth.

Asia Pacific industry is projected to grow steadily through 2037, impelled by growing number of fibromyalgia patients, along with rising healthcare spending and developing healthcare infrastructure.

The major players in the market include Pfizer Inc., AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Aptinyx Inc., Tonix Pharmaceuticals Holding Corp., Virios Therapeutics.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample